CD44-Targeted Cerasome Delivery for Vulnerable Plaque Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic techniques for vulnerable plaques are invasive and have low accuracy, while systemic drug administration is ineffective and risky, and existing nanocarriers lack specificity and stability for targeted drug delivery.
Innovation Solution
A cerasome delivery system utilizing a CD44 activator and hyaluronic acid derivative to target activated CD44 molecules on vulnerable plaques, providing stable and sustained drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive diagnostic techniques (coronary angiography, IVUS, OCT) are used, then diagnostic accuracy is improved, but patient risk and procedural complexity increase
Solution Approach 1:
The patent uses CD44-targeting ligands as intermediaries to bridge the gap between non-invasive imaging and vulnerable plaque detection. These ligands specifically bind to CD44 molecules on activated macrophages within vulnerable plaques, enabling indirect but accurate detection without invasive procedures
Solution Approach 2:
The patent replaces mechanical invasive diagnostic systems (catheters, ultrasound probes) with molecular recognition systems. The CD44-targeting ligands enable biochemical detection through specific molecular binding, substituting mechanical intervention with molecular specificity
2Ease of operation
If systemic drug administration is used, then drug distribution is improved, but therapeutic efficacy at target site and safety profile worsen
Solution Approach 1:
The patent applies local quality by conjugating therapeutic agents specifically to CD44-targeting ligands. This ensures that drugs are delivered with high concentration specifically to vulnerable plaque sites while maintaining simple systemic administration, creating localized high efficacy without sacrificing convenience
Solution Approach 2:
The CD44-targeting ligand acts as an intermediary carrier that bridges systemic circulation and local plaque delivery. It receives drugs in the bloodstream and selectively transports them to vulnerable plaques, maintaining administration convenience while dramatically improving therapeutic reliability
3Quantity of substance
If conventional nanocarriers are used for targeted delivery, then drug targeting is improved, but stability and specificity worsen
Solution Approach 1:
The patent employs composite materials by combining CD44-targeting ligands with stable nanocarrier structures. This creates a hybrid system that integrates the targeting specificity of molecular ligands with the stability and drug-loading capacity of engineered nanocarriers, achieving both high target concentration and system stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances diagnostic sensitivity and therapeutic efficacy by specifically targeting vulnerable plaques with high drug concentration and reduced side effects.
Implementation Method 1
the targeting ligand is a ligand capable of specifically binding to the activated CD44 molecule
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A cerasome delivery system for use in the targeted activation of a CD44 molecule, a preparation method and use thereof: a surface of a cerasome is partially modified by a targeting ligand, the targeting ligand being a ligand which may specifically bind to an activated CD44 molecule. The cerasome delivery system may be used for the diagnosis, prevention and treatment of vulnerable plaque or diseases associated with vulnerable plaque.